COVID-19: the new challenge for rheumatologists. One year later.
Clin Exp Rheumatol
; 39(1): 203-213, 2021.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1856817
ABSTRACT
At the beginning of COVID-19, we underlined that this pandemic was a new challenge for rheumatologists. On the one hand, it was necessary to clarify the impact of this new viral disease on the natural history of many rheumatic diseases and, on the other hand, to define the beneficial or harmful effects of the synthetic or targeted therapies used for their treatment. In addition, we have postulated that in view of the common pathogenetic mechanisms involved, the therapeutic armamentarium currently employed in the management of viral or idiopathic systemic autoimmune rheumatic diseases could be useful to control the "cytokine storm" induced by SARS-COV-2. One year later, in the present review we have analysed the progress of the knowledge on both these aspects and updated the algorithms initially proposed for a rational use of the synthetic and targeted anti-inflammatory and immunomodulatory agents in the management of COVID-19.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Reumatólogos
/
COVID-19
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Clin Exp Rheumatol
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
CLINEXPRHEUMATOL
Similares
MEDLINE
...
LILACS
LIS